Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

Author： Theou-Anton Nathalie   Faivre Sandrine   Dreyer Chantal   Raymond Eric  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.32, Iss.9, 2009-09, pp. : 717-734

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours

By Wolf Dominik  

Drug Safety, Vol. 32, Iss. 11, 2009-11 ,pp. : 1001-1015

Adis International

Access to resources Recommend Favorite

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?

By Nilsson Bengt   Nilsson Ola   Ahlman Håkan  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 457-468

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Sirolimus in Renal Transplantation

By Dirk R.J. Kuypers  

Drug Safety, Vol. 28, Iss. 2, 2005-01 ,pp. : 153-181

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Basiliximab in Renal Transplantation

By Boggi Ugo  

Drug Safety, Vol. 27, Iss. 2, 2004-01 ,pp. : 91-106

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

By Glimelius Bengt  

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 417-433

Adis International

Access to resources Recommend Favorite